(Q24311715)

4

0 references

Michael Jeltsch

10

0 references

Tuomas Tammela

5

0 references

Hilkka Lankinen

12

0 references

Wei Zheng

Wei Zheng

3

0 references

Päivi M Ojala

Päivi M Ojala

13

0 references

Wolfgang Holnthoner

Wolfgang Holnthoner

7

0 references

Nisse Kalkkinen

11

Nisse Kalkkinen

0 references

author name string

Denis Tvorogov

1

0 references

Andrey Anisimov

2

0 references

Simonas Laurinavicius

6

0 references

Hanna Heloterä

8

0 references

Tanja Holopainen

Crystallization of the receptor binding domain of vascular endothelial growth factor

9

0 references

language of work or name

English

0 references

publication date

14 December 2010

0 references

published in

Cancer Cell

0 references

volume

18

0 references

issue

6

0 references

page(s)

630-40

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

VEGF inhibition: insights from preclinical and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

The biology of vascular endothelial growth factors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Kaposi's sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Structure, stability and dynamics of the central domain of cardiac myosin binding protein C (MyBP-C): implications for multidomain assembly and causes for cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Structural analysis of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Monoclonal antibody strategies to block angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Lymphangiogenesis in development and human disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Protein structure prediction on the Web: a case study using the Phyre server

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Structure of a VEGF-VEGF receptor complex determined by electron microscopy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Vascular Endothelial Growth Factor-C (VEGF-C) and its Receptors KDR and flt-4 are Expressed in AIDS-Associated Kaposi’s Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Profound but Dysfunctional Lymphangiogenesis via Vascular Endothelial Growth Factor Ligands from CD11b+ Macrophages in Advanced Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021

Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2010.11.001

7 January 2021